{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:42:53Z","timestamp":1793058173757,"version":"4.5.0"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>With improvements in overall health attributable to newly available medications called highly effective modulator therapy, an increasing number of people with cystic fibrosis (CF) are pursuing pregnancy. However, the safety of these medications for pregnant people with CF and the fetus remains largely unknown. Limited data demonstrate a decline in patients' health and well-being after withdrawal of highly effective modulator therapy during pregnancy; however, both animal and human studies suggest an association between highly effective modulator therapy and cataracts in the offspring that requires further investigation. Use of highly effective modulator therapy can also affect the results of newborn screening and may influence fetal outcomes among fetuses affected by CF as a result of transplacental passage of highly effective modulator therapy. An ongoing prospective cohort study will likely provide more information for pregnant people with CF. Until then, multidisciplinary counseling continues to be critical for people with CF who are of reproductive age.<\/jats:p>","DOI":"10.1097\/aog.0000000000005732","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T17:01:25Z","timestamp":1734022885000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Pregnancy in People With Cystic Fibrosis Treated With Highly Effective Modulator Therapy"],"prefix":"10.1097","volume":"145","author":[{"given":"Jennifer L.","family":"Goralski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha N.","family":"Talati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily E.","family":"Hardisty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta L.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"R1-20260825","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMra1813799","article-title":"Muco-obstructive lung diseases","volume":"380","author":"Boucher","year":"2019","journal-title":"N Engl J Med"},{"key":"R2-20260825","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"R3-20260825","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"R4-20260825","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20260825","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","article-title":"Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Fajac","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R6-20260825","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2022.03.002","article-title":"Elexacaftor-tezacaftor- ivacaftor improves sinonasal outcomes in cystic fibrosis","volume":"21","author":"Stapleton","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R7-20260825","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"key":"R8-20260825","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"key":"R9-20260825","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1164\/rccm.201704-0717OC","article-title":"Tezacaftor\/ivacaftor in subjects with cystic fibrosis and F508del\/F508del-CFTR or F508del\/G551D-CFTR","volume":"197","author":"Donaldson","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"R11-20260825","doi-asserted-by":"crossref","first-page":"17534666221144211","DOI":"10.1177\/17534666221144211","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on depression and anxiety in cystic fibrosis","volume":"16","author":"Zhang","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"R12-20260825","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","article-title":"Elexacaftor\/tezacaftor\/ivacaftor treatment and depression-related events","volume":"209","author":"Ramsey","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"R13-20260825","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jcf.2023.06.009","article-title":"Longitudinal mental health trends in cystic fibrosis","volume":"22","author":"Hjelm","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R14-20260825","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1164\/rccm.202311-2159ED","article-title":"Questions and answers? Depression symptoms associated with elexacaftor\/tezacaftor\/ivacaftor treatment for cystic fibrosis","volume":"209","author":"Lee","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"R15-20260825","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R16-20260825","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"R17-20260825","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R18-20260825","doi-asserted-by":"crossref","first-page":"102301","DOI":"10.1016\/j.pupt.2024.102301","article-title":"Pharmacokinetic variability of CFTR modulators from standard and alternative regimens","volume":"86","author":"Rose","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"key":"R19-20260825","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/phar.2786","article-title":"Safety of elexacaftor\/tezacaftor\/ivacaftor dose reduction: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"R20-20260825","doi-asserted-by":"crossref","first-page":"1156621","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front Pharmacol"},{"key":"R22-20260825","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jcf.2020.12.011","article-title":"Elexacafator\/tezacaftor\/ivacaftor resolves subfertility in females with CF: a two center case series","volume":"20","author":"O'Connor","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R23-20260825","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/MCP.0000000000001009","article-title":"The modern landscape of fertility, pregnancy, and parenthood in people with cystic fibrosis","volume":"29","author":"Jain","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"R24-20260825","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00404-023-07153-y","article-title":"Unplanned pregnancies following the introduction of elexacaftor\/tezacaftor\/ivacaftor therapy in women with cystic fibrosis","volume":"308","author":"Dacc\u00f2","year":"2023","journal-title":"Arch Gynecol Obstet"},{"key":"R25-20260825","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jcf.2023.03.020","article-title":"Association between unplanned pregnancies and maternal exacerbations in cystic fibrosis","volume":"22","author":"Peng","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R26-20260825","first-page":"1545","article-title":"Reproductive counseling and care in cystic fibrosis: a multidisciplinary approach for a new therapeutic era","volume":"13","author":"McGlynn","year":"2023","journal-title":"Life (Basel)"},{"issue":"suppl 1","key":"R27-20260825","first-page":"S75","article-title":"Family-building and parenting considerations for people with cystic fibrosis","volume":"57","author":"Kazmerski","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"R28-20260825","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcf.2022.07.001","article-title":"Clinician attitudes and practices on pregnancy planning and care in cystic fibrosis","volume":"22","author":"Montemayor","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R29-20260825","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.whi.2012.10.003","article-title":"Enrolling pregnant women: issues in clinical research","volume":"23","author":"Blehar","year":"2013","journal-title":"Womens Health Issues"},{"key":"R31-20260825","doi-asserted-by":"crossref","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"key":"R32-20260825","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to lumacaftor and ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"R33-20260825","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R34-20260825","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros"},{"key":"R35-20260825","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R36-20260825","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R37-20260825","doi-asserted-by":"crossref","first-page":"1265138","DOI":"10.3389\/fphar.2023.1265138","article-title":"Ocular development after highly effective modulator treatment early in life","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Pharmacol"},{"key":"R38-20260825","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00404-023-06962-5","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor combination in pregnancy","volume":"309","author":"Cimino","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"R39-20260825","doi-asserted-by":"crossref","first-page":"e001289","DOI":"10.1136\/bmjresp-2022-001289","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"R40-20260825","doi-asserted-by":"crossref","first-page":"1274303","DOI":"10.3389\/fmed.2023.1274303","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","volume":"10","author":"Ripani","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R41-20260825","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/ppul.26706","article-title":"Use of CFTR modulators in special populations, part 1: pregnancy and lactation","volume":"58","author":"Elijah","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"R42-20260825","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","article-title":"Pregnancy in cystic fibrosis: review of the literature and expert recommendations","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R43-20260825","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamapediatrics.2022.2674","article-title":"Real-world associations of US cystic fibrosis newborn screening programs with nutritional and pulmonary outcomes","volume":"176","author":"Rosenfeld","year":"2022","journal-title":"JAMA Pediatr"},{"key":"R44-20260825","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1002\/ppul.25658","article-title":"Outcomes of infants born during the first 9 years of CF newborn screening in the United States: a retrospective Cystic Fibrosis Foundation Patient Registry cohort study","volume":"56","author":"Martiniano","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"R45-20260825","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/thoraxjnl-2019-213179","article-title":"Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK CF registry-based study","volume":"75","author":"Schl\u00fcter","year":"2020","journal-title":"Thorax"},{"key":"R46-20260825","doi-asserted-by":"crossref","first-page":"107679","DOI":"10.1016\/j.ymgme.2023.107679","article-title":"Why cystic fibrosis newborn screening programs have failed to meet original expectations\u2026thus far","volume":"140","author":"Farrell","year":"2023","journal-title":"Mol Genet Metab"},{"key":"R47-20260825","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jcf.2023.09.008","article-title":"Standards for the care of people with cystic fibrosis (CF): a timely and accurate diagnosis","volume":"22","author":"Castellani","year":"2023","journal-title":"J Cyst Fibros"},{"key":"R48-20260825","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ijns8030038","article-title":"Newborn screening for cystic fibrosis: a qualitative study of successes and challenges from universal screening in the United States","volume":"8","author":"Sontag","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"R49-20260825","doi-asserted-by":"crossref","first-page":"113595","DOI":"10.1016\/j.jpeds.2023.113595","article-title":"Late diagnosis in the era of universal newborn screening negatively affects short- and long-term growth and health outcomes in infants with cystic fibrosis","volume":"262","author":"Martiniano","year":"2023","journal-title":"J Pediatr"},{"key":"R50-20260825","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jcf.2023.07.003","article-title":"Letter to the editor: risk of false newborn screening after intra-uterine exposure to ETI","volume":"23","author":"De Wachter","year":"2024","journal-title":"J Cyst Fibros"},{"key":"R51-20260825","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"key":"R52-20260825","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R53-20260825","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jcf.2022.05.014","article-title":"Editorial\u2014the ethical implications of treating a pregnant woman to benefit the fetus","volume":"21","author":"Bennett","year":"2022","journal-title":"J Cyst Fibros"},{"key":"R54-20260825","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:00:56Z","timestamp":1787652056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000005732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005732","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"2024-05-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}